On the public citation graph

Incentivizing Drug Rediscovery: Exclusivity Extension and Priority Review for Repurposed Therapeutics

0 signed · 55 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/archinte.166.9.1021openalex-snapshot

Off-label Prescribing Among Office-Based Physicians

inferredcites →https://doi.org/10.1001/jama.2014.13235openalex-snapshot

Indication-Specific Pricing for Cancer Drugs

inferredcites →https://doi.org/10.1001/jama.2017.17535openalex-snapshot

Encouraging New Uses for Old Drugs

inferredcites →https://doi.org/10.1001/jama.2021.0006openalex-snapshot

A Court Decision on “Skinny Labeling”

inferredcites →https://doi.org/10.1001/jamainternmed.2017.4650openalex-snapshot

Strategies That Delay Market Entry of Generic Drugs

inferredcites →https://doi.org/10.1001/jamanetworkopen.2019.4791openalex-snapshot

Trends in Prices of Popular Brand-Name Prescription Drugs in the United States

inferredcites →https://doi.org/10.1001/jamanetworkopen.2022.39336openalex-snapshot

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021

inferredcites →https://doi.org/10.1001/jamanetworkopen.2025.8330openalex-snapshot

Rare Disease Drug Repurposing

inferredcites →https://doi.org/10.1007/s10198-021-01274-4openalex-snapshot

The economics of alternative payment models for pharmaceuticals

inferredcites →https://doi.org/10.1007/s40319-021-01088-0openalex-snapshot

Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity

inferredcites →https://doi.org/10.1016/j.ddstr.2011.06.008openalex-snapshot

Repositioned drugs: integrating intellectual property and regulatory strategies

inferredcites →https://doi.org/10.1016/j.drudis.2018.06.012openalex-snapshot

Renovation as innovation: is repurposing the future of drug discovery research?

inferredcites →https://doi.org/10.1016/j.pharmthera.2021.107930openalex-snapshot

Drug repurposing for COVID-19: Approaches, challenges and promising candidates

inferredcites →https://doi.org/10.1016/j.therap.2020.02.006openalex-snapshot

Drug repurposing in rare diseases: Myths and reality

inferredcites →https://doi.org/10.1016/j.tips.2013.03.004openalex-snapshot

Challenges and opportunities of drug repositioning

inferredcites →https://doi.org/10.1016/s1474-4422(23)00127-8openalex-snapshot

Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial

inferredcites →https://doi.org/10.1038/nrd.2018.168openalex-snapshot

Drug repurposing: progress, challenges and recommendations

inferredcites →https://doi.org/10.1038/nrd.2018.92openalex-snapshot

Overcoming the legal and regulatory barriers to drug repurposing

inferredcites →https://doi.org/10.1038/nrd1468openalex-snapshot

Drug repositioning: identifying and developing new uses for existing drugs

inferredcites →https://doi.org/10.1038/nrd3461openalex-snapshot

Mining for therapeutic gold

inferredcites →https://doi.org/10.1038/s41398-021-01724-wopenalex-snapshot

Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example

inferredcites →https://doi.org/10.1038/s41586-020-2577-1openalex-snapshot

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

inferredcites →https://doi.org/10.1080/13696998.2020.1867443openalex-snapshot

Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia

inferredcites →https://doi.org/10.1080/13696998.2021.1952795openalex-snapshot

Continuing trends in U.S. brand-name and generic drug competition

inferredcites →https://doi.org/10.1111/bph.13798openalex-snapshot

Drug repurposing from the perspective of pharmaceutical companies

inferredcites →https://doi.org/10.1111/deci.12574openalex-snapshot

Converting a drug from off‐label to on‐label use: Government subsidies and patient welfare

inferredcites →https://doi.org/10.1126/scitranslmed.abd5524openalex-snapshot

Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers

inferredcites →https://doi.org/10.1162/ajhe_a_00104openalex-snapshot

Examining Firm Responses to R&D Policy: An Analysis of Pediatric Exclusivity

inferredcites →https://doi.org/10.1186/s12913-022-08272-zopenalex-snapshot

Drug repurposing: a systematic review on root causes, barriers and facilitators

inferredcites →https://doi.org/10.1186/s40545-020-00282-8openalex-snapshot

Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

inferredcites →https://doi.org/10.1200/cci.19.00001openalex-snapshot

Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing

inferredcites →https://doi.org/10.1287/mnsc.2018.3123openalex-snapshot

Who Benefits When Prescription Drug Manufacturers Offer Copay Coupons?

inferredcites →https://doi.org/10.1287/mnsc.2019.3574openalex-snapshot

Outcome-Based Pricing for New Pharmaceuticals via Rebates

inferredcites →https://doi.org/10.1287/mnsc.2021.4096openalex-snapshot

Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?

inferredcites →https://doi.org/10.1287/mnsc.2021.4163openalex-snapshot

Designing Advance Market Commitments for New Vaccines

inferredcites →https://doi.org/10.1287/mnsc.2022.01721openalex-snapshot

Indication-Based Pricing for Multi-Indication Drugs

inferredcites →https://doi.org/10.1287/mnsc.2022.4634openalex-snapshot

Improving Access to Rare Disease Treatments: Subsidy, Pricing, and Payment Schemes

inferredcites →https://doi.org/10.1287/msom.2019.0822openalex-snapshot

Inducing Compliance with Postmarket Studies for Drugs Under FDA’s Accelerated Approval Pathway

inferredcites →https://doi.org/10.1287/msom.2020.0963openalex-snapshot

Flexible Drug Approval Policies

inferredcites →https://doi.org/10.1287/msom.2021.1009openalex-snapshot

The Effects of Patent Extension and Take-Back Regulation on Green Pharmacy

inferredcites →https://doi.org/10.1287/msom.2021.1051openalex-snapshot

Outcome-Based Reimbursement: The Solution to High Drug Spending?

inferredcites →https://doi.org/10.1371/journal.pmed.1002872openalex-snapshot

Competition and price among brand-name drugs in the same class: A systematic review of the evidence

inferredcites →https://doi.org/10.1377/forefront.20201204.541050openalex-snapshot

Generic Drug Repurposing For Public Health And National Security: COVID-19 And Beyond

inferredcites →https://doi.org/10.1377/forefront.20231101.123865openalex-snapshot

How The IRA Could Delay Pharmaceutical Launches, Reduce Indications, And Chill Evidence Generation

inferredcites →https://doi.org/10.1377/hlthaff.2014.1038openalex-snapshot

The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs

inferredcites →https://doi.org/10.1377/hlthaff.2015.1145openalex-snapshot

Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure

inferredcites →https://doi.org/10.1377/hlthaff.2016.1340openalex-snapshot

Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers

inferredcites →https://doi.org/10.1377/hlthaff.2017.1179openalex-snapshot

Evaluating The Impact Of The Orphan Drug Act’s Seven-Year Market Exclusivity Period

inferredcites →https://doi.org/10.1377/hlthaff.2020.01442openalex-snapshot

Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases

inferredcites →https://doi.org/10.1377/hlthaff.2022.01083openalex-snapshot

Drug Repurposing During The COVID-19 Pandemic: Lessons For Expediting Drug Development And Access

inferredcites →https://doi.org/10.2139/ssrn.4120736openalex-snapshot

Brand-Name versus Generic Drugs: An Empirical Study on Health Outcomes of Generic Atorvastatin Usage

inferredcites →https://doi.org/10.2217/cer-2017-0018openalex-snapshot

Indication-specific pricing of pharmaceuticals in the US healthcare system

inferredcites →https://doi.org/10.3386/w28168openalex-snapshot

Designing Advance Market Commitments for New Vaccines

inferredcites →https://doi.org/10.3389/fmed.2024.1387517openalex-snapshot

International regulatory and publicly-funded initiatives to advance drug repurposing

inferredcites →https://doi.org/10.37765/ajmc.2024.89495openalex-snapshot

Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.